BridgeMD
New treatment option for Hereditary Hemorrhagic Telangiectasia
Official title DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
ClinicalTrials.gov ID: NCT07623525
What this study is testing
What is DIAG723?
DIAG723 is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for hereditary hemorrhagic telangiectasia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with hereditary hemorrhagic telangiectasia (HHT). The study consists of three parts: Part A (dose escalation): Single ascending subcutaneous doses of DIAG723 are evaluated in sequential cohorts to assess safety, tolerability, and pharmacokinetics.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 13 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult patients ≥18 years with a clinical or genetic diagnosis of HHT
- Adequate hepatic and renal function
- Part B: Epistaxis and anemia or transfusion/iron history
- Part C: HHT with documented pre-capillary pulmonary arterial hypertension
You likely can't join if
- Active or recent systemic infection
- Recent thromboembolic events
- Use of anti-angiogenic drugs within 6 weeks
- Pregnancy or lactation
- Recent participation in another investigational study
The study team makes the final eligibility decision.
Where it's taking place
- Camperdown, New South Wales, Australia
- Randwick, New South Wales, Australia
- East Melbourne, Victoria, Australia
- Parkville, Victoria, Australia
- Grafton, Auckland, New Zealand
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 13 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Camperdown, New South Wales, Australia; Randwick, New South Wales, Australia; East Melbourne, Victoria, Australia; Parkville, Victoria, Australia; Grafton, Auckland, New Zealand. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.